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Context: Observational studies show discordant links between endogenous testosterone levels and 
cardiovascular diseases (CVD).
Objective: We assessed whether sex hormones and sex hormone–binding globulin (SHBG) are asso-
ciated with CVD in community-dwelling elderly men.
Design, Setting and Participants: Prospective study of incident CVD among 552 men ≥ 65 years in 
the MrOS Sleep Study without prevalent CVD and no testosterone therapy at baseline.
Outcomes:  Fasting serum levels of total testosterone and estradiol were measured using liquid 
chromatography-mass spectrometry, and SHBG by chemiluminescent substrate. The association of 
sex hormones and SHBG with incident coronary heart disease (CHD), cerebrovascular (stroke and 
transient ischemic attack) and peripheral arterial disease (PAD) events were assessed by quartile and 
per SD increase in proportional hazards models.
Results: After 7.4 years, 137 men (24.8%) had at least 1 CVD event: 90 CHD, 45 cerebrovascular and 
26 PAD. The risk of incident CVD events was not associated with quartiles of baseline sex hormones 
or SHBG (all P ≥ 0.16). For +1 SD in total testosterone, the multivariate-adjusted hazard ratio was 
1.04 (95% CI, 0.80-1.34) for CHD, 0.86 (0.60-1.25) for cerebrovascular, and 0.81 (0.52-1.26) for PAD 
events. When analyzed as continuous variables or comparing highest to low quartile, levels of bioa-
vailable testosterone, total estradiol, testosterone/estradiol ratio and SHBG were not associated with 
CVD events.
Conclusions: In community-dwelling elderly men, endogenous levels of testosterone, estradiol, and 
SHBG were not associated with increased risk of CHD, cerebrovascular, or PAD events. These results 
are limited by the small number of events and should be explored in future studies.
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Cardiovascular diseases (CVD) are the most common cause of death and comorbidities. 
CVD predominate among men compared to premenopausal women, while postmenopausal 
women catch up in terms of CVD incidence and prevalence [1]. The exact mechanisms of 
this difference by sex are not known, but a potential effect of sex hormones on CVD risk has 
long been debated.
Multiple observational studies have explored the association of endogenous testosterone 
(T) and cardiovascular outcomes, albeit with inconsistent results and methodology. Even 
after focusing on community-dwelling populations, Araujo et  al found multiple studies 
examining this association and more recent studies have been published since this review 
[2]. In the large EPIC-Norfolk study in Europe and the Rancho Bernardo Study in the 
United States, lower endogenous T levels were associated with increased risk of cardiovas-
cular mortality [3, 4]. A large Swedish study showed a reduced 5-year cardiovascular risk 
among elderly men in the highest T quartile, overall and in separate analyses of coronary 
heart disease (CHD) and cerebrovascular diseases (hospitalization for stroke or transient 
ischemic attack, or death from stroke) [5]. In an Australian study of elderly men, higher T 
and dihydrotestosterone (DHT) levels were associated with a lower incidence of stroke, but 
not CHD [6]. At the other end of the spectrum, men with T below the 10th percentile had 
an increased risk of ischemic stroke [7]. In a smaller study of 171 Japanese men aged 30 
to 69 years, those in the lowest T tertile had a higher overall CVD risk [8]. Taken together, 
these studies suggest an increased CVD risk associated with low T levels.
Other studies reported no association of T with CVD risk, but with other sex hormones. 
Among middle-aged men of the Framingham cohort, the highest quartile of estradiol (E2) 
was associated with a lower CVD risk, but there was no association across quartiles of T 
and dehydroepiandrosterone sulfate [9]. In the Cardiovascular Health Study, there was no 
association of T with CVD risk, but a curvilinear relationship of DHT with CVD risk [10]. 
In the Atherosclerosis Risk in Communities study, low T levels were associated with CVD 
classical risk factors only in the cross-sectional analysis, but not in the longitudinal analysis 
[11]. In contrast, postmenopausal women with high T/E2 ratios, or T absolute levels had 
increased CVD risk in the MESA study [12]. Other potential mechanisms would include the 
increased duration of the QTc interval in women, and linked with sex hormone levels and 
ratios [13], or mediated by differences in lipid levels.
In this context, we assessed whether endogenous T, in total or bioavailable forms, in ad-
dition to E2 and sex hormone–binding globulin (SHBG) were associated with incident CVD 
events in a prospective cohort of 552 community-dwelling elderly men.
Materials and Methods
Participants and design
From March 2000 to April 2002, the Osteoporotic Fractures in Men (MrOS) Study enrolled 
5994 community-dwelling men aged ≥ 65 years at 6 study sites [14, 15]: Birmingham, AL; the 
Monongahela Valley near Pittsburgh, PA; Minneapolis, MN; Palo Alto, CA; San Diego, CA; 
and Portland, OR. Exclusion criteria were the inability to walk without assistance and bilat-
eral hip replacement. Each site and coordinating center’s institutional review board approved 
the study protocol, and written informed consent was obtained from all participants.
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Subsequently a random sample of 1602 men was selected for baseline sex hormone as-
sessment to determine the association with bone mineral density [16] (Fig. 1). Of this group, 
819 (51.1%) participated in an ancillary study of sleep disorders (MrOS Sleep Study) from 
December 2003 to March 2005 [17]; the average time between the baseline and the sleep 
study visits was 3.4 years. Among these 819 participants, we excluded those with incom-
plete data on medications (n = 32); those with exogenous alterations to sex hormones at 
baseline (n = 71, reasons detailed in Fig. 1); those with incomplete data on sex hormone 
levels (n = 16) and cardiovascular outcomes (n = 12); and those who reported a history of 
CVD (n = 136). The final sample of the main analysis therefore included 552 men (Fig. 1). 
When compared to the 1602 men randomly selected for sex hormone measurement, the 552 
men in our analysis were younger, more physically active, had higher low-density lipopro-
tein (LDL)-cholesterol and lower triglycerides, and were less likely to use anti-hypertensive, 
lipid-lowering, and diabetes medication. There was no major difference between the 2 
groups in terms of smoking, body mass index (BMI), systolic blood pressure, high-density 
lipoprotein (HDL), or fasting glucose.
1602 randomly selected
participants for sex 
hormone measurement
819 participants in MrOS
sleep study (recruitment
in 2003-05)
783 excluded from MrOS sleep study:
- 537 declined to participate
- 110 deceased
- 87 not contacted because sleep study had met 
its recruitment goal
- 39 not eligible (CPAP or oxygen use)
- 10 dropped out of the study
5994 participants in
MrOS main study 
(recruitment in 2000-02)
552 participants in final 
sample for analyses
28 excluded for missing exposure/outcome:
- 16 with missing data on sex hormone levels
- 12 with missing data on CVD outcomes
136 excluded for prior cardiovascular disease 
before the baseline visit of MrOS main study
32 excluded for missing medication info
71 excluded for exogenous alteration to sex hormones
at baseline (more than one reason possible):
- 20 on oral corticosteroids
- 3 on anti-androgen
- 1 on androgen
- 8 self-reported current testosterone injection
- 49 self-reported prior treatment for prostate cancer:
  - 33 had radiotherapy
  - 14 had hormone shots/pills
  -   2 had an orchidectomy
Figure 1. Flow of participants of MrOS main study and MrOS sleep study. Participants of 
the MrOS main study were randomly selected for additional measurement of their sex hor-
mone levels (see Methods), then a subset was randomly selected for an ancillary study on 
sleep, with exclusions depicted in the right boxes, thus leading to 552 participants in the final 
sample of this study. Abbreviations: CPAP, continuous positive airway pressure; CVD, cardio-
vascular diseases; MrOS, the Osteoporotic Fractures in Men Study.
4 | Journal of the Endocrine Society | doi: 10.1210/jendso/bvaa038
Cardiovascular outcomes
After recruitment in the MrOS Sleep Study, participants were surveyed for incident CVD 
events every 4 months via postcard and/or phone contact with a 99% response rate [17]. 
When participants reported a potential event, the local study center gathered clinical docu-
mentation such as notes, laboratory results, diagnostic studies, and discharge summaries. 
Death certificates were obtained for all fatal events. All fatal and nonfatal cardiovas-
cular events up until July 29, 2014, were adjudicated at the central coordinating center 
by a board-certified cardiologist blinded to laboratory results using standardized outcome 
definitions. An expert adjudicator independently reviewed a random subset of 5% of all re-
ported events to ensure accuracy in diagnosis.
The primary outcomes of this analysis were (1) CHD events defined by ST or non-ST el-
evation acute myocardial infarction, CHD sudden death, coronary artery bypass surgery or 
revascularization, hospitalization for unstable angina, ischemic congestive heart failure, 
and other CHD events not listed above; 2) cerebrovascular events (stroke > 24 hours or tran-
sient ischemic attack < 24 hours); and 3) peripheral arterial disease (PAD) events defined as 
acute arterial occlusion, dissection or rupture, and vascular surgery. Multiple events in one 
hospitalization were categorized as separate events. In case of multiple CVD events, only 
the first (incident) event of the same category (CHD, cerebrovascular or PAD events) was 
retained for the analysis.
Clinical measurements
At the baseline visit, participants completed a questionnaire on demographic character-
istics, medical history, smoking, and alcohol consumption. Physical activity was assessed 
using the Physical Activity Scale for the Elderly (PASE, score range 0-793 with higher 
scores representing greater physical activity) [18, 19]. To assess their functional status, 
men were asked how many of 5 instrumental activities of daily living (IADL, score range 
0-5) they had any difficulty with. The IADLs consisted of walking 2 to 3 blocks outside on 
level ground, climbing 10 steps without resting, preparing meals, heavy housework, and 
shopping for groceries or clothes.
Participants were asked to bring all prescription medications used in the previous 
30 days on a daily or almost daily basis. Each medication was matched to its active drug 
agent(s) based on the Iowa Drug Information Service Drug Vocabulary (College of Pharmacy, 
University of Iowa, Iowa City, IA) [20].
Height was measured on Harpenden stadiometers and weight on standard balance beam 
or digital scales, with participants wearing light clothing without shoes. BMI was calcu-
lated as weight in kg/height in meters squared. Systolic blood pressure was measured once 
in each arm using a conventional mercury sphygmomanometer, and the average of the 2 
measurements was obtained.
Lab assays
Serum samples were collected at baseline in the morning after an overnight fast and stored 
at −70 C degrees. Aliquots from each participant were assayed in duplicate and the values 
averaged. A combined gas chromatographic negative ionization tandem mass spectrometry 
and liquid chromatographic electrospray tandem mass spectrometry bioanalytical method 
were used to measure total testosterone, estradiol, and estrone in serum (Taylor Techonology, 
Princeton, NJ) [16]. Detection ranges were 2.5 to 320 ng/dL for testosterone, 0.625 to 80 pg/
mL for estradiol and 1.56 to 200 pg/mL for estrone. Testosterone values above the detection 
range were reanalyzed after dilution. The intra-assay and inter-assay coefficients of vari-
ation were, respectively, 2.5% and 6% for testosterone, 6.4% and 10.1% for estradiol, and 
5.2% and 12.9% for estrone. The total testosterone as measured in the MrOS Study was 
part of the cross-calibration process to develop harmonized testosterone measurement [21].
doi: 10.1210/jendso/bvaa038 | Journal of the Endocrine Society | 5
The testosterone-to-estradiol (T:E2) ratio was calculated by dividing the respective total 
serum levels (after converting both totals to ng/mL). SHBG concentration was determined 
on an Immulite Analyzer with chemiluminescent substrate (Diagnostic Products Corp., Los 
Angeles, CA). The standard curve range was 0.2 to 180 nmol/L, the intra-assay coefficient 
of variation 4.6% and the inter-assay coefficient of variation 5.8%. Albumin concentration 
was considered as a constant value of 4.3 g/dL. Bioavailable (non SHBG-bound) fractions of 
testosterone and estradiol were then calculated using mass action equations by Sodegard 
et al [22] and Vermeulen et al [23].
Total cholesterol, HDL-cholesterol and triglycerides were measured using a Roche 
COBAS Integra 800 automated analyzer which was calibrated daily (Roche Diagnostics 
Corp., Indianapolis, IN). LDL-cholesterol levels were calculated with the Friedewald equa-
tion [= Total cholesterol − HDL-cholesterol – (Triglycerides * 0.2) (all in mg/dL)] [24]. Fasting 
glucose was analyzed enzymically on a Hitachi 917 Autoanalyzer, and fasting insulin 
concentrations by a 2-site immune-enzymometric assay using a Tosoh 600 II auto-analyzer.
Statistical analysis
Participant baseline characteristics were compared across quartiles of total and bioa-
vailable testosterone; total and bioavailable E2; the ratio of total T to total E2 (T:E2) and 
SHBG, using either analyses of variance or Kruskal-Wallis tests (continuous variables) 
or chi-squared tests of homogeneity (categorical variables) where appropriate. The per-
centage of participants with cardiovascular events were compared across total testosterone 
quartiles using chi-squared tests of homogeneity. The associations between baseline sex 
hormone levels and subsequent risk of incident cardiovascular events were determined for 
the composite cardiovascular outcome (incident CHD, cerebrovascular, and/or PAD event) 
and for each cardiovascular outcome individually: incident CHD event, incident cerebro-
vascular event, and incident PAD event. For participants who had more than one type of 
event (e.g., incident CHD and PAD), time to event was based on the first event to be experi-
enced. Cox proportional hazards regression models were used to assess these associations. 
We estimated the hazard ratios (HR) with 95% confidence intervals (CI) of cardiovascular 
events by quartiles of sex hormone levels. The initial model was adjusted for age at inclu-
sion and study enrollment site. To account for the potential effect of covariates, we assessed 
multivariate (MV) models adjusted for multiple variables (MV1 to MV5 models) and report 
results from the full multivariate (MV5) model. In addition to the analysis by quartiles de-
tailed above, we assessed the HR per 1 standard deviation (SD) increase in the sex hormone 
levels. We also tested whether the relationship between the sex hormones and incident 
cardiovascular events was nonlinear by testing the significance of a quadratic term for the 
sex hormones in the models. Finally, we tested effect modification by age in analyses strat-
ified by the median age for the study sample (< 72 vs ≥ 72 years). Statistical analyses were 
conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC).
Results
The 552 male subjects without CVD at baseline had a mean age of 72.4 years (SD, 5.4) and 
a mean BMI of 27.6 kg/m2 (SD, 3.6) (Table 1). The majority were white (91.3%), with no dif-
ference of ethnic group distribution across T quartiles (P = 0.44). Participants within higher 
T quartiles had a lower weight and BMI (both P < 0.001), and a borderline lower prevalence 
of diabetes mellitus (P = 0.06), consistent with lower fasting glucose and insulin levels (both 
P < 0.001). Antihypertensive drugs were more often prescribed to those in lower quartiles 
of testosterone (P = 0.02), with no prominent drug class. Participants in lower quartiles of 
testosterone were also more frequently prescribed statins (P = 0.01), and had lower levels of 
total cholesterol, LDL, and HDL-cholesterol (all P ≤ 0.04) and higher levels of triglycerides 
(P < 0.001). After excluding those on lipid-lowering drugs (n = 126), only the associations 
with HDL-cholesterol and triglycerides remained significant (data not shown).
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During a mean follow-up of 8.4 years (SD 2.2) after inclusion in the MrOS Sleep Study, 23 
(4.2%) of the 552 men terminated the study. Out of the 152 deaths, 49 (32.2%) were of car-
diovascular origin (Table 2). Of the 552 participants, 137 (24.8%) participants had at least 
1 CVD event of any type during a mean follow-up of 7.4 ± 3.0 years, 90 (16.3%) had at least 
1 CHD event during a mean follow-up of 7.7 ± 2.8 years, 45 (8.2%) had at least 1 cerebro-
vascular event during a mean follow-up of 8.1 ± 2.5 years and 26 (4.7%) had at least 1 PAD 
event during a mean follow-up of 8.2 ± 2.4 years.
The percentage of men experiencing cardiovascular events during follow-up did not differ 
across total testosterone quartiles (Table 2). Likewise, there was no difference in the per-
centage of men who died from cardiovascular causes or from any cause across the total 
testosterone quartiles. There was no difference in risk of incident CHD, incident cerebro-
vascular, or incident PAD events for men in quartiles 2, 3, and 4 of serum total testosterone 
compared to those in the lowest quartile of total testosterone in minimally adjusted or fully 
adjusted models (all P ≥ 0.18, Fig. 2). In analyses by quartiles of bioavailable testosterone, 
total estradiol and SHBG, there was again no difference in risk of any of the cardiovascular 
events for men in quartiles 2 to 4 compared with those in quartile 1 of the sex hormones in 
any of the models (data not shown).
The HR of incident cardiovascular events per 1 SD increase in levels of each sex hormone 
were not significant in age and study site-adjusted analyses, nor after adjustment for mul-
tiple cardiovascular risk factors (Table 3).
There was no evidence of interaction between sex hormone levels and age (<72 years 
vs ≥ 72 years) for prediction in risk of CVD outcomes (all P ≥ 0.08). There was no evidence 
of a non-linear relationship between sex hormone levels and the risk of any cardiovascular 
event, except for a possible non-linear relationship between the T:E2 ratio and risk of any 
cardiovascular event (Table 4, p for quadratic term = 0.06 in age and study site-adjusted 
model, and 0.09 in fully adjusted model).
Discussion
In our study of community-dwelling elderly men, the levels of endogenous testosterone 
or other sex hormones were not associated with incident cardiovascular events, including 
CHD, cerebrovascular, and PAD events, over 8.4 years of follow-up.
Our results contrast with those of other observational studies. The meta-analysis by 
Araujo et al [2] that concluded that lower T levels are associated with an increased risk 
of all cause and CVD mortality, but this review did highlight the large heterogeneity in 
findings across individual studies, and not specifically CVD events as done in the current 
study. These inconsistent results may be due to differences between the studied populations, 
the baseline cardiovascular risk, the analysis methods chosen, or the sex hormone assays 
[25]. The latter was the reason for a recent standardization effort of T assays, which relied 
on measurements by mass spectrometry, for which the MrOS Study was 1 of the 4 cohorts 
used to harmonize T levels [21]. Another potential explanation is the use of total vs free 
vs bioavailable T as the exposure parameter in different studies, which is still debated, al-
though the latest recommendations suggest that it is best to rely on total T and to measure 
SHBG to evaluate hypogonadism in men [26]. In our study, there was no difference of HRs 
of CVD events between total and bioavailable T, contrary to other studies [27]. To avoid con-
fusion, future studies or re-analysis of older studies would need to check for differences in 
the predictive power for CVD event risk with total T measured with mass spectrometry or 
a CDC-certified assay.
As the knowledge regarding CVD event risk and its link with sex hormones is still open to 
debate, it is important for clinicians caring for elderly men to screen for agreed-upon cardi-
ovascular risk factors, i.e., hypertension, hyperlipidemia, smoking cessation, obesity, and/or 
diabetes mellitus. Interestingly, treating these other risk factors can lead to improvements 
of T levels. For example, weight loss led to increased T levels in the EMAS study [28]. In 
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our study, adjustment for other conditions and their treatments did not change the null 
associations of sex hormones and SHBG with the risk of CVD events.
This study is observational and the small number of participants who were on hormone-
altering treatments were excluded from the analysis (Fig.  1). Thus, this study does not 
address the effects of T prescription, which has surged over the past decade [29], with 
wide differences between countries [30]. As highlighted by the recently updated Endocrine 
Society guidelines on T replacement therapy [26], clinicians should be wary of potential 
cardiovascular complications of exogenous T in older men. The controversy about T replace-
ment in older men has been ongoing for years and has faced increased scrutiny by the US 
Food and Drug Administration (FDA) [31, 32] and the European Medicines Agency [33]. 
Of note, other groups do not share these views and strongly advocate in favor of limiting T 
therapy for men with documented T deficiency [34].
Multiple meta-analyses have assessed the effect of T replacement on CVD with incon-
sistent results and criteria [35]. The Testosterone Trials grouped 7 randomized controlled 
trials (RCTs) assessing the effects of T replacement on multiple outcomes after 1 year: The 
Cardiovascular Trial showed an increased progression of coronary artery plaques after 
1 year of T [36], but no difference in CVD events, although these studies were not designed 
to assess clinical cardiovascular endpoints and had low power [37]. Another RCT of T gel was 
terminated prematurely due to more cardiovascular adverse events compared to placebo, 
but the premature termination of the study, the low number of events and the inclusion of 
men ≥ 65 years of age with limited mobility and a high prevalence of comorbidities preclude 
any definite conclusion [38]. Another trial of T in older men by the same group showed no 
difference in carotid intima-media thickness or coronary artery calcium score after 3 years 
of T replacement, but was not powered to conclude on CVD events and cardiovascular safety 
ref.
0.1
0.2
0.3
0.5
1.0
2.0
3.0
5.0
H
R
Q1 Q2 Q3 Q4
Coronary heart disease events
ref.
0.1
0.2
0.3
0.5
1.0
2.0
3.0
5.0
H
R
Q1 Q2 Q3 Q4
Cerebrovascular events
ref.
0.1
0.2
0.3
0.5
1.0
2.0
3.0
5.0
H
R
Q1 Q2 Q3 Q4
Peripheral vascular events
Figure 2. Hazard ratios of coronary heart disease, cerebrovascular and peripheral vascular 
events by quartiles of serum total testosterone. The hazard ratios (HR) of coronary heart 
disease events by quartiles of serum total testosterone (T) from fully-adjusted multivariate 
models are shown in panel A (P for trend 0.82), for cerebrovascular events in panel B (P for 
trend 0.72) and for peripheral vascular events in panel C (P for trend 0.37). Quartile 1 (Q1: 
T < 307 ng/dL) was the reference group (ref.) for comparisons with quartile 2 (Q2: T 307-
391 ng/dL), quartile 3 (Q3: T 391-495 ng/dL) and quartile 4 (Q4: T ≥ 495 ng/dL). Vertical bars 
represent 95% confidence intervals.
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[39]. On the other hand, an intention-to-treat observational cohort study reported benefits 
of T replacement on CVD outcomes [40]. Current clinical knowledge is therefore based on 
retrospective cohorts with their inherent limitations: Some observational studies reported 
increased CVD event risk with T replacement [41, 42], while other registries concluded that 
T replacement was not associated with higher rates of CVD events [43]. This open question 
on the potential benefits and harms of T replacement still needs more definite and longer 
RCTs [26]. The CVD outcomes will be assessed in an industry-sponsored RCT launched 
Table 4. Risk of Any Cardiovascular Event (Coronary Heart Disease Event, Cerebrovascular Event, 
or Peripheral Arterial Disease Event) by Quartile of Serum Sex Hormones and SHBG in Multivariate 
Models
Sex hormone  
and models
Hazard ratio (95% CI) by quartiles of sex hormone measures P for  
linear 
trend
P for  
quadratic 
termQuartile 1 Quartile 2 Quartile 3 Quartile 4
Total Testosterone < 307 ng/dL 307-391 ng/dL 391-495 ng/dL ≥ 495 ng/dL   
 Initial model 1.00 (ref.) 0.94 (0.59, 1.50) 0.75 (0.45, 1.22) 1.10 (0.70, 1.73) 0.94 0.94
 MV1 1.00 (ref.) 0.98 (0.61, 1.57) 0.71 (0.42, 1.18) 1.03 (0.63, 1.67) 0.80  
 MV2 1.00 (ref.) 0.99 (0.61, 1.61) 0.69 (0.41, 1.17) 1.08 (0.66, 1.77) 0.95  
 MV3 1.00 (ref.) 0.93 (0.57, 1.51) 0.74 (0.44, 1.27) 1.06 (0.63, 1.78) 0.97  
 MV4 1.00 (ref.) 0.96 (0.58, 1.56) 0.68 (0.40, 1.17) 1.01 (0.60, 1.69) 0.72  
 MV5 1.00 (ref.) 0.93 (0.55, 1.55) 0.64 (0.36, 1.14) 1.04 (0.60, 1.79) 0.82 0.84
Total Estradiol < 17.8 pg/mL 17.8-21.9 pg/mL 21.9-26.6 pg/mL ≥ 26.6 pg/mL   
 Initial model 1.00 (ref.) 1.08 (0.68, 1.70) 1.01 (0.63, 1.62) 0.97 (0.59, 1.60) 0.86 0.89
 MV1 1.00 (ref.) 1.09 (0.69, 1.74) 1.04 (0.65, 1.68) 1.01 (0.61, 1.68) 0.99  
 MV2 1.00 (ref.) 1.09 (0.68, 1.73) 0.97 (0.59, 1.59) 0.98 (0.59, 1.62) 0.82  
 MV3 1.00 (ref.) 1.12 (0.70, 1.82) 1.07 (0.65, 1.75) 1.08 (0.64, 1.83) 0.83  
 MV4 1.00 (ref.) 1.24 (0.76, 2.02) 1.12 (0.67, 1.87) 1.04 (0.60, 1.79) 0.98  
 MV5 1.00 (ref.) 1.15 (0.69, 1.90) 0.96 (0.56, 1.63) 0.98 (0.56, 1.70) 0.76 0.91
T:E2 ratio < 143 143-181 181-227 ≥ 227   
 Initial model 1.00 (ref.) 1.62 (1.02, 2.60) 1.44 (0.89, 2.34) 0.86 (0.51, 1.45) 0.50 0.06
 MV1 1.00 (ref.) 1.50 (0.93, 2.42) 1.34 (0.81, 2.22) 0.73 (0.42, 1.29) 0.23  
 MV2 1.00 (ref.) 1.53 (0.94, 2.51) 1.39 (0.83, 2.33) 0.81 (0.45, 1.44) 0.38  
 MV3 1.00 (ref.) 1.48 (0.90, 2.42) 1.28 (0.76, 2.15) 0.70 (0.39, 1.28) 0.21  
 MV4 1.00 (ref.) 1.50 (0.92, 2.47) 1.23 (0.72, 2.08) 0.68 (0.37, 1.25) 0.16  
 MV5 1.00 (ref.) 1.53 (0.92, 2.56) 1.20 (0.69, 2.09) 0.73 (0.39, 1.36) 0.24 0.09
SHBG < 35.1 nmol/L 35.1-45.1 nmol/L 45.1-57.3 nmol/L ≥ 57.3 nmol/L   
 Initial model 1.00 (ref.) 0.74 (0.45, 1.23) 1.11 (0.70, 1.78) 1.15 (0.72, 1.86) 0.31 0.34
 MV1 1.00 (ref.) 0.72 (0.43, 1.19) 1.04 (0.64, 1.68) 1.06 (0.64, 1.74) 0.53  
 MV2 1.00 (ref.) 0.76 (0.45, 1.27) 1.07 (0.65, 1.76) 1.10 (0.66, 1.84) 0.49  
 MV3 1.00 (ref.) 0.72 (0.43, 1.23) 1.13 (0.68, 1.87) 1.07 (0.63, 1.83) 0.47  
 MV4 1.00 (ref.) 0.71 (0.42, 1.19) 0.99 (0.60, 1.64) 0.91 (0.53, 1.55) 0.98  
 MV5 1.00 (ref.) 0.72 (0.42, 1.24) 1.05 (0.62, 1.80) 0.94 (0.53, 1.65) 0.87 0.50
We estimated the hazard ratios (with 95% confidence interval) of cardiovascular events per quartile of sex 
hormones, compared to the lowest quartile used as the reference group. The initial model was adjusted for age 
at inclusion and study site, followed by multivariate (MV) models to account for the potential effect of covariates:
- Initial model: Adjusted for age at inclusion and study site.
- MV1 model: Initial model + further adjusted for smoking status, physical activity (PASE score) and body mass 
index.
- MV2 model: MV1 model + further adjusted for systolic blood pressure and the use of anti-hypertensive medication.
- MV3 model: MV1 model + further adjusted for LDL cholesterol, HDL cholesterol, triglycerides and the use of 
lipid-lowering medication.
- MV4 model: MV1 model + further adjusted for fasting plasma glucose and any current diabetes treatment.
- MV5 model: Initial model + further adjusted for all aforementioned covariates, i.e., age at inclusion, study site, 
smoking status, physical activity (PASE score), body mass index, systolic blood pressure, use of anti-hypertensive 
medication, LDL cholesterol, HDL cholesterol, triglycerides, use of lipid-lowering medication, fasting plasma glu-
cose and any current diabetes treatment.
Abbreviations: CI, confidence interval; HDL, high density lipoprotein; LDL, low density lipoprotein; MV, multivar-
iate model; PASE, physical activity scale for the elderly; SHBG, sex hormone-binding globulin; T:E2 ratio, total 
testosterone / total estradiol ratio.
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in 2018 to satisfy the safety concerns of the FDA (TRAVERSE trial, clinicaltrials.gov ID 
NCT03518034).
Our study has strengths and limitations. It was conducted at 6 different sites across 
the US, including more than 500 community-dwelling elderly white men followed up over 
8.4 years with very low attrition rate. While a lot of other studies relied mostly on death 
certificates or registry [2], our study used death certificates as the primary source of data 
then all cardiovascular outcomes were adjudicated by a panel of cardiologists. The sample 
size of the study is limited to draw firm conclusions, especially in the context of a fairly 
healthy populations, with a low mean BMI, low smoking rates, and not many comorbidities. 
Because it is an observational study and participants on hormone-altering treatments were 
excluded, we cannot conclude on the causal pathway of endogenous T, nor can we assess the 
effects of T replacement. Moreover, the higher rate of statin users in participants whose T 
was below the median could be presumably due to a higher underlying CVD risk, but the 
lipid profile prior to statin use is not known in this study. Finally, as in most epidemiologic 
studies, sex hormones were measured at baseline only and measurement predated collec-
tion of CVD outcomes by an average of 3.5  years. We cannot assess the changes in sex 
hormone levels over time and their effects on cardiovascular outcomes. However, we used 
high-throughput liquid chromatography–tandem mass spectrometry method to measure 
sex hormones, which are less subject to bias and interference than other assays [21]. 
Statistical power was limited due to the relatively small number of outcomes events, espe-
cially stroke and PAD events, even prior to attempting to stratify the analysis according to 
age. Therefore the analyses stratified by age and adjusted with multiple variables (Table 4) 
should be seen as hypothesis-generating in the context of past and ongoing studies on the 
association of endogenous T levels and the risk of stroke and PAD events.
In conclusion, endogenous T levels were not associated with risk of CHD, cerebrovascular or 
PAD events in this observational study of elderly community-dwelling men. The effects of en-
dogenous and exogenous T on the incidence of CVD events in older men require further study.
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